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Abstract: Although the large majority of mitochondrial proteins are nuclear encoded, for their correct
functioning mitochondria require the expression of 13 proteins, two rRNA, and 22 tRNA codified
by mitochondrial DNA (mtDNA). Once transcribed, mitochondrial RNA (mtRNA) is processed,
mito-ribosomes are assembled, and mtDNA-encoded proteins belonging to the respiratory chain are
synthesized. These processes require the coordinated spatio-temporal action of several enzymes,
and many different factors are involved in the regulation and control of protein synthesis and in
the stability and turnover of mitochondrial RNA. In this review, we describe the essential steps of
mitochondrial RNA synthesis, maturation, and degradation, the factors controlling these processes,
and how the alteration of these processes is associated with human pathologies.
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1. The Mitochondrial DNA
Given its endosymbiotic bacterial origins, it is not surprising that the organization of DNA in
mitochondria is similar to that of bacterial DNA. The bacterial genome is compacted by a factor of
104-fold that of its volume to form the bacterial nucleoid, and in a similar way the mitochondrial DNA
(mtDNA) is compacted and organized in discrete protein–DNA complexes distributed throughout
the mitochondrial matrix [1]. mtDNA was first described in the 1960s [2] and completely sequenced
in 1981 by Anderson et al. [3]. Despite the differences between nucleoids in mammals and in yeast,
most of the information on the structure and composition of the nucleoid comes from studies on
yeast that have been fundamental in understanding the mammalian nucleoids. During the 1970s,
scientists were able to stain the mtDNA in vivo and noticed sub-mitochondrial structures near the
inner membrane, later called nucleoids, where the mtDNA was located. Each nucleoid can contain
more than one mtDNA molecule and each mitochondrion can contain tens (for yeast) or hundreds (for
mammalians) of nucleoids. Moreover, each nucleoid can be considered as a unit of genetic segregation
in the mitochondria, as every nucleoid acts as an independent genetic unit.
Mitochondrial DNA comprises 0.1–2% of the total DNA in most mammalian cells. There are
several unique features of the mtDNA: human mtDNA is circular, 16 kbp long, and inherited from the
mother. It encodes two rRNAs, 22 tRNAs, and 13 proteins, all of which are involved in the oxidative
phosphorylation process [4]. The intragenic sequence is almost absent or limited to a few bases [5]
and mtDNA does not have histones, instead it is organized in nucleoid structures. A large number of
experiments showed that multiple copies of mtDNA could be found in each nucleoid, usually from
two to 10 copies each, depending on the cell line studied [6]. However, quantitative analysis of the size
and mtDNA content of the nucleoid in cultured mammalian cells suggests that an average nucleoid
may contain five to seven mtDNA molecules packed in a space of 70 nm [6], similar to the bacterial
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genome. Tight packaging of the mtDNA is achieved thanks to the proteins present in the nucleoid,
such as the mitochondrial transcription factor TFAM.
2. The Transcription Process
Two different strands can be recognized in the mtDNA: the heavy strand rich in guanine bases,
which also contains the majority of mitochondrial coding genes, and the light strand, encoding only for
the MT-ND6 (NADH-ubiquinone oxidoreductase chain 6) protein and eight tRNAs. Both strands are
transcribed at the same time, giving origin to very long transcripts, of almost mtDNA length, that are
subsequently processed. Transcription seems to take place in the nucleoids due to the presence of
the mitochondrial transcription machinery. However, experiments performed with 5-bromouridine
(BrU) aimed at tracking the progress of the nascent RNA transcripts showed that newly transcribed
mtRNAs are also found in discrete foci situated in close proximity to mitochondrial nucleoids, called
mitochondrial RNA granules [6–8], which will be described in detail later.
The essential enzymatic machinery dedicated to the mtDNA transcription is completely different from
the nuclear one and is composed by few proteins: the DNA-directed RNA polymerase (POLMRT) [9,10],
the mitochondrial transcription factor A (TFAM) [11,12], the mitochondrial transcription factors B1 and
B2 (TFB1M and TFB2M) [13,14], the mitochondrial transcription elongator factor (TEFM), a single
strand binding protein (SSBP), and the family of mitochondrial transcription termination factors
(mTERF1-4). Additionally, MRPL12 (39S ribosomal protein L12) acting as a complex with POLMRT
and TEFM is required for the processivity during the elongation phase and to prevent the termination
of the transcription at conserved sequence block 2 (CSB2) [12,15,16]. It is in the non-coding region of
the D-loop that mitochondrial translation is regulated by the heavy strand promoters 1 and 2 (HSP1
and HSP2), the light strand promoter (LSP) [17], the transcription termination-associated sequences
TAS1 and TAS2, and the conserved sequence blocks1 and 2 (CSB1 and CSB2). HSP2 is the sequence
promoting the transcription of almost full-length of the heavy strand [18,19] while HSP1 is only
responsible for the transcription of the two ribosomal RNAs that terminate just after the tRNALeu.
Regarding the transcription of the light strand, LSP1 is a unique site where the transcription can start
and terminates at CSB1, but the majority of initiation events from this site stop 200 bp downstream the
promoter, at the CSB2 site [20]. CSB2 is a conserved G-rich sequence and its function is to terminate the
transcription of the 7S RNA for the replication of the mtDNA, regulating the switch between mtDNA
replication and transcription [20,21].
Transcription is initiated by the binding of TFAM to an high affinity site −10/−15 bp from the
site of transcription start, creating a stable U-turn [22]. Once in this position, the POLMRT can bind
directly to the TFAM unit that recruits the protein to the promoter. POLMRT can slide in the DNA from
positions −50 to −60, approximately, and the complex is unable to start the process until TFB2M binds
the complex TFAM–POLMRT and the fully assembled initiation complex encircles the promoter. In fact,
TFB2M is required for the conformational changes needed for the transcription starting [23]. Among
all genes involved in mitochondrial translation, TFAM is the only one whose mutation has been shown
to cause human diseases. Mutations in the TFAM gene are linked to an autosomal recessive disorder
with infantile-onset progressive liver failure. mtDNA copy number is decreased, and patients present
defects in the respiratory processes [24]. Mutation of other components of the transcription machinery
seems not to be causative of any pathology in humans. TFAM is also involved in neurodegenerative
pathologies, controlling the mtDNA copy number [25].
To enhance the processivity of the translation process, TEFM can interact with the catalytic,
C-terminal part of POLRMT, and depletion of TEFM impairs transcription elongation both in vitro
and in knock-down cell lines [16]. TEFM stimulates POLRMT interactions with an elongation-like
DNA:RNA template, and the protein is present at the promoter before the initiation of transcription.
It also helps the POLMRT with the transcription of long stretches of RNA and to bypass regions with
secondary RNA structures (e.g., tRNAs) [15,26]. It was recently demonstrated that TEFM is able
to enhance mtRNAP transcription elongation by reducing the frequency of long-lived pauses and
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shortening their durations and helps to overpass the CSB2 sequence to continue the transcription of
the full polycistronic RNA [26].
The process of mitochondrial transcription termination is still unclear. There is still a debate if
MTERF1 is really needed for the termination of all the transcription processes that originate from
the three different promoters of the control region. Recent studies have shown that knock-down
mice for the MTERF1 gene do not have any notable consequence on the phenotype, and the levels
of ribosomal and messenger RNA are unaffected. However, biochemical studies have shown that
MTERF1 only partially terminates H-strand transcription [27], whereas transcription in the opposite
direction (L-strand transcription) is almost completely blocked (Figure 1).
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3. Regulation of Transcription by Protein Direct Binding to mtDNA
Many different proteins are involved in the regulation of transcription, such as hormones, nuclear
transcription factors, and chromatin remodeling enzymes which are also able to interact with the
mitochondrial DNA, and RNA/DNA modifying enzymes. Here we propose a brief overview of the
mtDNA transcription regulation operated by these factors (Table 1).
3.1. Hormones
One of the first proteins discovered to be involved in the regulation of transcription is the thyroid
hormone T3, which is able to promote the mtDNA transcription by directly binding the mtDNA
genes [28]. More recent is the observation that a dominant negative form of the thyroid hormone is
able to bind the thyroid receptor elements present in the 12S gene and in the D-loop region [29–31].
The cAMP-responsive element binding protein (CREB) was found to be able to specifically bind to
a natural or a palindromic thyroid-responsive element. Moreover, this protein specifically binds to
a direct repeat 2 sequence located in the D-loop of the mitochondrial genome [32]. Glucocorticoid
hormones were also found to be in mitochondria where they modulate the transcription binding to the
glucocorticoid receptor present in the mitochondrial inner membrane [33,34]. The estrogen receptor
(ER) was found in the mitochondria of cardiac cells. It was hypothesized that E2 (17β-estradiol) and
ERβ-mediated cardioprotection was dependent on mtDNA transcription encoding for mitochondrial
respiration activity. It was also demonstrated that E2 can also increase the ER β mtDNA binding activity
followed by an increase in complex V encoding gene expression [35]. Melatonin was also recently
described as a potential hormone that can control the mtDNA expression through the reduction of
several mitochondrial transcription factors. It was demonstrated that melatonin was able to decrease,
at both mRNA and protein levels, TFAM expression as well as other proteins such as transcription
factors TFB1M and TFB2M, interfering with mtDNA transcription [36].
3.2. Nuclear Transcription Factors
Several nuclear transcription factors are also able to bind the mtDNA. Recently, Marinov and
colleagues through chromatin immunoprecipitation (ChIP) sequencing from seven different human cell
lines demonstrated the presence of diverse transcription factors to be bound to the mtDNA. From this
Int. J. Mol. Sci. 2019, 20, 2221 4 of 23
study, the most enriched ones were CEBPb (CCAAT/enhancer-binding protein beta), c-Jun, JunD, MafF,
MafK, Max, NFE2, and Rfx5 (DNA-binding protein RFX5). Most of them were found to be enriched in
the D-loop structure as expected, but some were also found to be able to bind sequences in proximity
of the OXPHOS (Oxidative phosphorylation) subunits encoding genes with differences between the
cell lines studied [37]. Some of them have been better characterized for their function in regulating
the mitochondrial transcription. c-Jun, a well-known nuclear transcription factor, was shown to
decrease mtDNA transcription in concert with other enzymes involving the retinoid X receptor (RXR)
pathway [38]. NFATc1 (Nuclear factor of activated T-cells, cytoplasmic 1) is a transcription factor
involved in the differentiation of human mesenchymal stem cells in osteoblasts. This protein was also
found to be in mitochondria and to interact with the D-loop region inhibiting the transcription of some
crucial genes such as Cyt-b (Cytochrome b) and MT-ND1 (NADH-ubiquinone oxidoreductase chain 1),
therefore acting as a negative regulator of mtDNA transcription during the calcification process [39].
3.3. Chromatin Remodeling Enzymes
It is well established that, in eukaryotes, methylation on cytosine at the CpG sequences in the
nuclear DNA (5mCpG) regulates the transcription of the genes through alteration of the chromatin
structure. However, mtDNA is devoid of histones and nucleosomal chromatin, so the mechanisms
by which these CpG islands are methylated in mitochondria must be different, but they are still
unknown. As mentioned before, the best-characterized and abundant protein binding duplex DNA is
the HMG-box protein TFAM, which is permanently associated with mtDNA [40]. TFAM is the only
factor that plays a clear structural role in mtDNA organization in nucleoids, similar to the role of
histones for the nuclear DNA or the histone-like proteins in bacteria [41,42]. This protein is probably
the major factor responsible for the tight packaging of the mtDNA, so it plays a role in mtDNA
topology [43]. TFAM is able to bind the double helix of the DNA and acts as a packaging protein
mostly on the central region of the mtDNA because the estimation of TFAM concentration is too
low for the coverage of the entire mtDNA molecule [41,44,45]. It was estimated that one molecule
of TFAM can bind the DNA in regular intervals of 20 bp [46–48] but since the protein acts as a
homodimer, two molecules of TFAM bind the DNA in intervals of 35–40 bp [46,47]. Although it has
been suggested that TFAM lacks binding sequence specificity, some researchers proposed mtDNA
binding site preferences [49], especially at regions that tend to adopt G-quadruplex structures (GQP)
in vitro [50] but not in vivo [51].
Due to the tight coverage of the mtDNA with TFAM and to the non-sequence specificity of the
interaction, this protein must interact with many CpG islands in the mtDNA. There is a growing
amount of evidence showing that some of these CpG islands could be methylated and that this
can influence the transcription of genes possessing this modification, similar to what happens in
the nucleus. It was proposed by Minczuk and colleagues that the occurrence of 5mCpG has the
potential to impact TFAM-mtDNA recognition in mammalian cells. The authors demonstrated that
the methylation of CpG sequences in the HSP can increase the binding activity of TFAM inducing
TFAM multimerization at these sites, without changing the compaction of the DNA. Additionally,
5mCpG seems to have a clear and context-dependent effect on transcription: it was shown that CpG
methylation in the HSP1 promoter strongly increases the transcription starting from this site [52].
It was recently suggested that mtDNA chromatin-like organization is gradually established during the
embryogenesis of mammalian cells, showing an increasing accumulation in the density of footprinting
sites, revealing a dynamic achievement of mtDNA coverage during embryonic development and in the
regulatory regions (D-loop) [53]. In fact, not only the methylation of CpG sequences but also different
chromatin remodeling enzymes can be found in the mtDNA.
MOF (males absent on the first; also known as MYST1 or KAT8) is the major lysine acetyl
transferase (KAT) responsible for the deposition of H4K16ac in flies and mammals [54–56], and
it was shown to directly bind mtDNA controlling mitochondrial transcription. In its absence,
mitochondrial transcription is downregulated with catastrophic consequences on metabolism and
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respiratory function [57]. On the contrary, STAT3 (signal transducer and activator of transcription
protein 3) is able to bind the mtDNA and TFAM, which influences the transcription of mitochondrial
genes. It was demonstrated that the ablation of STAT3 in keratinocytes results in an increased
mitochondrially encoded gene transcripts [58]. SIRT1 (NAD-dependent protein deacetylase sirtuin-1)
was also found to be present in mitochondria-forming stable complexes with TFAM inside the nucleoids
and to be able to bind the mtDNA [59].
Dnmt (DNA methyl-transferase 1) is a methyl transferase enzyme commonly associated with gene
silencing and was found to accumulate in the mitochondria of retinal endothelial cells treated with
high glucose concentrations. In the same background, methylation of the mtDNA was also increased
in the D-loop causing a decreased transcription of the mtDNA, resulting in dysfunctional mitochondria
and accelerated apoptosis [60].
3.4. MitomiRs
MicroRNAs (miRNAs) are a class of small RNAs able to regulate gene expression through
interference with the translation process. A particular class of these miRNAs (mitomiRs) were found
to be enriched in proximity of mitochondria and inside these organelles, controlling the mitochondrial
behavior [61]. It is still not clear how mitomiRs are imported into the organelle, but it seems that
the polynucleotide phosphorylase (PNPase), a ribonuclease present both in the matrix and in the
intermembrane space of the mitochondria, is the protein deputized for this role [62]. Several studies
have identified the mtDNA as a source and target of mitomiRs [63–65]. Although the canonical
mechanism by which these molecules exert their function is the prevention of translation, it was
proposed that they can also act directly on the mtDNA to block the transcription process. It was in fact
demonstrated that mitomiR 2392 can regulate the gene expression of mtDNA in tongue squamous
carcinoma cells. The presence of this miRNA in mitochondria is able to reverse the chemoresistance of
these cells, directly binding, with Argonaut 2, to specific sequences in the H-strand of the mtDNA,
partially blocking the transcription, resulting in the reduction of OXPHOS complexes activity [66].
4. Nuclear Factors Indirectly Influencing Transcription
Many factors are involved in the mitochondrial transcription regulation and the crosstalk with
the nucleus. Nuclear proteins play a central role in the indirect control of the mtDNA transcription
and mitochondrial function. The most studied factors influencing mitochondrial activity are the
nuclear respiratory factors 1 and 2 (NRF1 and NRF2) and yin yang 1 (YY1), along with p53 and the
peroxisome-proliferator-activated receptor coactivator (PGC1).
NRF1 and NRF2 have been linked with the transcription of many genes involved in mitochondrial
function, not only the nuclear encoded subunits of the respiratory chain but also proteins belonging
to the transcription machinery [67]. It has been demonstrated that they are able to enhance the
transcription of mitochondrial biogenesis genes during exercise in rats and in response to diverse
stress challenges [68,69]. TFAM and mitochondrial RNA processing enzymes are target genes of NRF1,
and TFBM1 and TFBM2 were also recently demonstrated to be their target. These two proteins enhance
mtDNA transcription in the presence of TFAM and mitochondrial RNA polymerase. Moreover,
it has been shown that the same NRF-recognizing sites are also needed for the activation of PGC1
enzymes and PRC (PGC-1-related coactivator) activation and that TFB genes, TFAM and PCG1 or PRC,
are upregulated in cells where mitochondrial biogenesis is induced [70].
The physiological activation of these PGC1 family members and PRC coactivators is also required
for inducing and integrating signals controlling cell growth, metabolism and cell differentiation,
and mitochondrial biogenesis [71]. One of the targets of PGC1α is YY1, which in concert with the
mammalian target of rapamycin (mTOR) can regulate the mitochondrial transcription. mTOR is a
kinase and is a fundamental component in nutrient sensing and energy pathways in the cell. mTOR
also contributes to the control of mitochondrial oxidative activities [72]. Inhibition of the mTOR protein
in skeletal muscle cells results in the loss of PGC-1a expression and nuclear respiratory factors, leading
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to a decrease in mitochondrial genes expression and OXPHOS impairment. This function is mediated
by YY1, which was demonstrated to be required for rapamycin-dependent repression of respiration
genes, a common target of mTOR and PGC1α [73].
The tumor suppressor p53 has a well-known role in the maintenance of the mitochondrial DNA,
contrasting mtDNA mutagenesis [74]. p53 was also demonstrated to be involved in controlling the
mitochondrial mtDNA copy number. In fact, p53 was firstly described to be in mitochondria in 2012
with a role in the start of the necrosis process [75]. The loss of p53 in null mouse and knock-down human
fibroblasts determines the mtDNA depletion and reduction of TFAM, compromising transcription,
protein synthesis, respiration, and mitochondrial mass [76]. Moreover, it was shown that p53 is able
to inhibit the entrance of the NF-κB (Nuclear factor kappa-light-chain-enhancer of activated B cells)
family member RelA into the mitochondria, impeding the repression of mitochondrial transcription
actuated by this protein in the absence of p53 [77].
Another key factor in the regulation of mitochondrial function is the HIF1α (hypoxia inducible
factor-1α) protein. This protein usually mediates the adaptation of the cell to conditions such as
hypoxia and oxidative stress through regulation of gene expression. The way by which HIF1α
regulates cell responses to these stresses in mitochondria is still not well understood. It was shown
that HIF1α was able to translocate inside mitochondria after induced oxidative stress in human cells.
Moreover, overexpression of a mitochondrially targeted form of the protein helps to attenuate apoptosis
and promote expression of mtDNA-encoded mRNAs independently from the expression of nuclear
OXPHOS subunits [78].
Finally, a higher mechanism to control mitochondrial gene expression is the co-expression of
mitochondrial genes and the nuclear genes encoding for the respiratory chain complex proteins.
Both the genetic systems can adapt to enhance or reduce the transcription depending on the energy
demand of the cell [67,79,80]. It was demonstrated that there is a co-expression of genes inside each
one of the five OXPHOS complexes from both the nuclear and mitochondrial parts. Although common
sequences (core promoters) were found in the promoter regions of the OXPHOS genes, the authors
were unable to find a common pattern of OXPHOS-specific transcription factors for each set of genes
expressed [81].
Table 1. Factors affecting mitochondrial transcription. The table reports on protein belonging to the
three classes of factors (hormones, chromatin remodeling enzymes, and nuclear transcription factors)
mentioned in the text for their role in regulating mitochondrial transcription. The protein functions of
hormones were obtained from the Human Metabolome Database, and those of all other proteins were
obtained from UniProt.




T3 thyroid hormone is normally synthesized and
secreted by the thyroid gland. T3 is a
triiodothyronine and is primarily responsible for
regulation of metabolism.
Promotes mtDNA transcription
directly binding to mtDNA in the




Glucocorticosteroids are generally required for
stress response and are involved in several
processes such as inflammation, allergy, collagen
diseases, asthma, adrenocortical deficiency,
shock, and some neoplastic conditions.
Promotes mtDNA transcription
directly binding to the GR inserted
into the inner membrane or to
glucocorticoid responsive
elements in the mtDNA [34].
17β-Estradiol and ERβ
Estradiol is the most potent form of mammalian
estrogenic steroids estradiol is a potent
endogenous antioxidant, attenuates induction of
redox sensitive transcription factors, hepatocyte
apoptosis and hepatic stellate cells activation. It
has been reported to induce the production of
interferon (INF)-gamma in lymphocytes, and
augments an antigen-specific primary antibody
response in human peripheral blood
mononuclear cells.
Promotes mtDNA transcription;
in particular, it increases Complex
V gene expression [35].
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Table 1. Cont.
Class Protein Name Function Effect on MitochondrialTranscription
Melatonin
Melatonin is a biogenic amine produced by the
pineal gland. Melatonin regulates the
sleep–wake cycle by chemically causing
drowsiness and lowering the body temperature.
It is also implicated in the regulation of mood,
learning and memory, immune activity,
dreaming, fertility, and reproduction and is also
an effective antioxidant. Most of the actions of
melatonin are mediated through the binding and
activation of melatonin receptors.
Reduces mtRNA transcription
indirectly by influencing the
mRNA and protein levels of





Binds to the mitochondrial light strand promoter
and functions in mitochondrial transcription
regulation. Required for accurate and efficient
promoter recognition by the mitochondrial RNA
polymerase. Promotes transcription initiation
from the HSP1 and the light strand promoter by
binding immediately upstream of transcriptional
start sites. Is able to unwind DNA. Bends the
mitochondrial light strand promoter DNA into a
U-turn shape via its HMG boxes. Required for
maintenance of normal levels of mitochondrial








Histone acetyltransferase may be involved in
transcriptional activation. May influence the
function of ATM. It is involved in acetylation of
nucleosomal histone H4 producing specifically
H4K16ac. It may be involved in acetylation of
nucleosomal histone H4 on several lysine





Signal transducer and transcription activator that
mediates cellular responses to interleukins and
other growth factors. Acts as a regulator of
inflammatory response by regulating
differentiation of naive CD4+ T-cells into T-helper
Th17 or regulatory T-cells. Involved in cell cycle
regulation by inducing the expression of key




NAD-dependent protein deacetylase that links
transcriptional regulation directly to intracellular
energetics and participates in the coordination of
several separated cellular functions such as cell
cycle, response to DNA damage, metabolism,
apoptosis, and autophagy. Can modulate
chromatin function through deacetylation of
histones and can promote alterations in the





Methylates CpG residues. Preferentially
methylates hemimethylated DNA. Associates
with DNA replication sites in S phase
maintaining the methylation pattern in the newly
synthesized strand. It is responsible for









Transcription factor that recognizes and binds to
the enhancer heptamer motif 5′-TGA[CG]TCA-3′.
Involved in activated KRAS-mediated
transcriptional activation of USP28 in colorectal
cancer (CRC) cells.
Decreases mtDNA transcription in
concert with retinoid X receptor
pathway [38].
NFATc1
Plays a role in the inducible expression of
cytokine genes in T-cells, especially in the
induction of the IL-2 or IL-4 gene transcription.
Also controls gene expression in embryonic
cardiac cells. Is required for osteoclastogenesis
and regulates many genes important for
osteoclast differentiation and function.
Inhibits transcription of Cyt-b and
MT-ND1 through binding of the
D-loop region [39].
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Table 1. Cont.
Class Protein Name Function Effect on MitochondrialTranscription
NRF1/2
Transcription factors activate the expression of
the EIF2S1 (EIF2-alpha) gene. Links the
transcriptional modulation of key metabolic
genes to cellular growth and development.
Implicated in the control of nuclear genes





expression of TFAM, TFB1M,
TFB2M, RNA processing enzymes,
PGC1, and PRC [70].
PGC1 and PRC
PGC1 plays the role of a stimulator of
transcription factors and nuclear receptors
activities. Activates transcriptional activity of
estrogen receptor alpha, nuclear respiratory
factor 1 (NRF1), and glucocorticoid receptor in
the presence of glucocorticoids.
PRC acts as a coactivator during transcriptional
activation of nuclear genes related to
mitochondrial biogenesis and cell growth. It is
involved in the transcription co-activation of
CREB and NRF1 target genes.
Fundamental to mtDNA
transcription. Increases
transcription of NRF1 [71].
mTOR
Serine/threonine protein kinase, which is a
central regulator of cellular metabolism, growth,
and survival in response to hormones, growth
factors, nutrients, energy and stress signals.
mTOR directly or indirectly regulates the
phosphorylation of at least 800 proteins.
Functions as part of two structurally and
functionally distinct signaling complexes
mTORC1 and mTORC2 (mTOR complex 1 and 2).
Increases mtDNA transcription
through modulation of PGC and
YY1 [73].
YY1
Multifunctional transcription factor that exhibits
positive and negative controls on a large number
of cellular and viral genes by binding to sites






A multifunctional enzyme that mainly acts as a
tumor suppressor in many tumor types and
induces growth arrest or apoptosis depending on
the physiological circumstances and cell type.
Involved in cell cycle regulation as a
trans-activator that acts to negatively regulate
cell division by controlling a set of genes required
for this process.
Fundamental for the maintenance
and transcription of mtDNA.
Inhibits the entrance of RelA into
mitochondria [77].
HIF1α
Functions as a master transcriptional regulator of
the adaptive response to hypoxia. Activates,
under hypoxic conditions, the transcription of
over 40 genes whose protein products increase





5. Processing of Mitochondrial Transcripts
From their synthesis to their degradation, mtRNAs undergo several stages of maturation and
modification for the correct production of mtDNA-encoded proteins. As mitochondrial DNA replication
and transcription need to be spatio-temporally regulated to adapt to the metabolic demand of the cell,
so must the basic stages of mitochondrial gene expression. To achieve this, mitochondria restrict mtRNA
processing and maturation to dynamic protein structures called mitochondrial RNA granules (MRGs),
which provide a regulatory function for post-transcriptional processing, allowing all mtRNAs to be
fully mature before protein synthesis [82,83]. To confirm and better understand the function of these
structures, in 2015 Antonicka et al. [84] characterized the proteome of the granules using GRSF1, a core
component of the granule [7,8], as a bait Some proteins found by the authors were already confirmed
in the literature, such as RNaseP [8] and more interestingly the so-called “mitochondrial degradosome”
composed of hSUV3 (ATP-dependent RNA helicase SUPV3L1) and PNPase [85], confirming the
hypothesis that MRGs are not only sites of RNA processing, but also of RNA degradation and turnover.
Mass spectrometry analysis of immune-precipitated fractions showed a large number of proteins
responsible for the post-transcriptional processing of the primary polycistronic transcript, such as
MRPP (Mitochondrial ribonuclease P protein) 1, -2, and -3, RNA-modifying enzymes such as TFB1M
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(Dimethyladenosine transferase 1), PTCD3 (Pentatricopeptide Repeat Domain 3), and the mitochondrial
poly-A polymerase. In addition, proteins belonging to the mitochondrial translation machinery, as well
as structural proteins of the small (mt-SSU) and large (mt-LSU) mitochondrial ribosomal subunits,
aminoacyl tRNA synthetases, and factors involved in ribosome assembly and disassembly, were present
in the analysis. These data suggest that MRGs are also involved in mitochondrial ribosome biogenesis
and in mitochondrial translation regulation, with a function analogous to that of the nucleolus, where
initial steps of ribosomal assembly are performed [86,87]. It is possible that both mtDNA and its
transcription products are portioned within non-membrane bound compartments to provide a greater
degree of spatio-temporal regulation of mtRNA processing. The last stage of mtRNA life was suggested
to take place in specific foci, called D-foci (degradation foci), composed mostly of the mitochondrial
degradosome [85,88]. It has been shown that these foci co-localize with the MRGs, although it is still
not clear whether they form a subset of MRGs or are separate entities with a distinct composition and
purpose. In these structures, several catalytic mitochondrial enzymes and other mitochondrial and
non-mitochondrial proteins, whose role remains to be established, were also found.
The transcription of mtDNA gives rise to two polycistronic transcripts that must be somehow
processed to release different RNA species. Most of the mRNAs and mt-rRNA-coding regions are
separated by mt-tRNAs. These RNAs are separated from each other according to the generally
accepted mt-tRNA punctuation model [3,5]. The mitochondrial RNA-processing machinery initiates
the cleavage of the mt-tRNA sequences, freeing the mt-rRNAs or mt-mRNAs that they intersperse.
However, not all the mRNA and are flanked by a mt-tRNA coding sequence, such as ATP6/8 and COIII
or ND5 and Cyt B.
It has been recently proposed that the early stages of the mitochondrial transcription can take place
co-transcriptionally inside the mitochondrial RNA granules. Indeed, most of the proteins involved
in mtRNA processing were found to be part of the MRG proteome [7,8,89]. In particular the 5′-end
of the mt-tRNAs is processed by the protein complex RNaseP, composed of MRPP1, -2, and -3 that
are found in the granules [8,90]. MRPP1 is a m1G9-methylase, while MRPP2 is a dehydrogenase also
involved in other cellular functions [91]. These two proteins form a subcomplex that also participates
in tRNA modification [92]. MRPP3 is responsible for the hydrolysis of the phosphodiester bond [93].
The knockout of any of these proteins causes an accumulation of the RNA precursor molecule, reducing
the steady-state levels of the mature form of mt-tRNAs and some mt-mRNAs [94]. Mutations of the
gene encoding for MRPP1 (TRMT10C) were reported in infants presenting at birth with lactic acidosis,
hypotonia, feeding difficulties, and deafness. Fibroblasts from individuals carrying missense mutations
of the gene show decreased levels of mtRNA precursors, indicating an impaired mtRNA processing
and an inefficient mitochondrial protein synthesis [95,96]. In addition, a novel mutation in the MRPP2
encoding gene (X-linked gene, HSD17B10) was found to be causative of intractable epilepsy and global
developmental delay. The pathogenicity of the mutation is due to a general mitochondrial dysfunction
caused by the reduction in maturation of mt-tRNAs [95,97].
RNaseZ (also named Zinc phosphodiesterase ELAC protein 2 (ELAC2)) is responsible for
the 3′-end processing of the mt-tRNAs, but this protein was not found to be part of the MRG
proteome [98,99]. Mutations in the ELAC2 gene were confirmed to be the cause of an infantile
hypertrophic cardiomyopathy characterized by complex I deficiency and accumulation of mt-tRNA
precursors in skeletal muscle and fibroblasts as well as impaired mitochondrial translation [100].
It was then proposed that the primary transcripts undergo an initial round of processing, partially
co-transcriptionally, inside the MRGs, while a second part of the maturation takes place later and
outside the granules. In this case, the knockout of the protein causes the accumulation of mtRNA
precursors [94,99].
Recently, other proteins were described in the MRGs that could have a function in the processing
of the primary transcript. GRSF1 (G-rich sequence factor 1) is an RNA-binding protein that has been
shown to co-localize with newly synthesized mtRNA and with MRPP1. The loss of the protein results
in a decrease in the mature form of some transcripts [7,8]. PTCD1 is another protein implicated in
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the mtRNA metabolism. This protein directly interacts with RNaseZ and seems to play a role in the
coordination of 3′-end processing [94,101].
mt-tRNAs released from the primary transcript need to reach their mature form and a stabilized
conformation to be used during the translation process. mt-tRNAs undergo a different variety of
chemical modifications that can be divided into two categories: those able to confer the tRNA the
correct structural stability and folding and those that coordinate the proper tRNA function altering their
interaction with other factors [102]. The mammalian mitochondrial ribosome is composed, like the
cytosolic one, of two subunits of different sizes, the small subunit 28S (mtSSU) and the large subunit
39S (mtLSU) [103–106]. Both of them are composed of the mitochondrially encoded rRNAs 12S and
16S, respectively, and the ribosomal proteins that are codified by nuclear genes and imported into
the mitochondrial matrix. Mitochondrial rRNAs undergo post-transcriptional modifications to be
functional; however, differently from the cytosolic ones, the range of modifications is less wide, and
they do not require any nucleolytic processing [102,107,108] (Figure 2).
6. Maturation of Mitochondrial mRNA
Once released from the primary transcript, mt-mRNAs undergo post-transcriptional modification.
Stabilization of the mitochondrial mRNAs is very different and simpler compared with the process
of nuclear-encoded mRNAs. On the contrary, the degradation process shows similarities to the
compartmentalization and the degradation process that takes place in the cytoplasm [102].
6.1. Polyadenylation
The first difference between the maturation process of the nuclear-encoded mRNAs and that of
the mitochondrial ones is the lack of 5′CAP modification as well as the absence of introns. The 3′-end
of mt-mRNAs is modified to have a poly-A tail much shorter than nuclear mRNAs that can go from
45 to 55 nucleotides, with some exceptions [109]. Indeed it was found that ND6 completely lacks the
poly-A tail and is immediately competent for translation, while ND5 can be either oligo-adenylated or
not adenylated at all [109]. Poly-A tails are synthesized by a non-canonical poly-A polymerase (mtPAP)
that localizes in MRGs, suggesting again that the first maturation steps take place co-transcriptionally
in the granules [110–113]. The knock-down of mtPAP or a decrease in the polyadenylation leads to
impaired mitochondrial translation and the disruption of the mitochondrial respiratory function [111].
The exact role of the poly-A tail in mitochondrial transcripts is still unclear [114]. Seven out of 13
mt-mRNAs do not encode a complete stop codon for translation termination. Most of them are
cut out when the mt-tRNAs are nucleolitically cleaved from the primary transcript, often leaving a
“U” or “UA”. For this reason, it was suggested that the poly-A tail added after that cleavage has
the function to complete the stop codons [3,5]. Although the classical role of the poly-A tail is to
stabilize and increase the half-life of the transcripts; in the mitochondrial compartment, this is not
always the case. It was shown that the poly-A tail can decrease the stability of Cytochrome c oxidase
subunit I, II, III (COI, COII, COIII), and ATP6/8 (ATP synthase protein) and increase the stability of
ND1, ND2, ND3, ND4, ND4L, ND5, and Cyt. B. The mechanism of this transcript-specific role of
polyadenylation remains to be elucidated [115–117]. A mutation in the gene encoding mtPAP was
found to cause a form of spastic ataxia with optic atrophy in the Amish population. RNA extracted
from the cells of these patients showed shortened polyA tails, which consequently caused an aberrant
and inefficient translation and a defective activity of the respiratory chain complexes [118]. OligoA
polymerization was retained by the mutated protein, and it was demonstrated that this difference
in the polyA tail has differential effects on transcript stability that were dependent on the particular
species of transcript [113]. The phosphodiesterase 12 (PDE12) protein, a mitochondrial 2′ and 3′
phosphodiesterase [115,119], is responsible for the removal of the poly-A tail, but this activity was
shown only in vitro and in cultured cells, after overexpression of the protein [115].
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6.2. Non-Canonical Capping
In eukaryotic cells, mRNAs are normally capped with a 5′ end N7 methyl guanosine (m7G)
cap that promotes their translation and stability. Mitochondrial mRNAs do not have this type of
modification. It was demonstrated that in human cells, like in Escherichia coli [120], mRNAs can harbor
a 5′-end nicotinamide adenine dinucleotide (NAD+) cap [121], which in contrast to the m7G cap does
not support translation but instead promotes mRNA decay [122]. This kind of modification was
recently detected also in mitochondria of human cells. It was also found that POLMRT is able to add an
NAD+ cap to mitochondrial RNAs species in vitro and that the enzyme is able to initiate transcription
of NADylated RNA from the LSP promoter. This suggests that the NAD+ capping can influence both
the translation and the replication process, given that the majority of transcription events that originate
from the LSP promoter give rise to the 7S RNA needed for the replication of mtDNA [123].
6.3. Processing Regulation by MRG Proteins
The G-rich sequence factor 1 (GRSF1) is one of the first mtRNA granule proteins to be described.
This protein preferentially binds RNAs derived from three genes (the ND6 mRNA and the long
noncoding RNAs for Cyt. B and ND5, from the LS) and all these genes contain consensus sequences for
GRSF1. It was demonstrated that the silencing of this protein causes alterations in mitochondrial RNA
stability, aberrant mtRNA processing, abnormal loading of mRNAs and lncRNAs on the mitochondrial
ribosome, and impaired ribosome assembly [7]. It was also shown that GRSF1 can interact with RNase
P, thus being involved directly into the processing of the primary transcripts [8]. These data implicate
GRSF1 as a key regulator of post-transcriptional mitochondrial gene expression.
The FASTK (FASTK and FAS-activated serine/threonine kinase 1–5) family proteins are non-canonical
structured RNA binding proteins, all of which are located in mitochondria. All family members have
a different role in the regulation of mtRNA biology, from processing to translation [124]. FASTK is
localized both in the nucleus and in mitochondria, where it interacts with GRSF1 and ND6 mRNA.
Since ND6 mRNA is one of the non-canonical transcripts, it was proposed that FASTK binds this RNA
protecting it from the PNPase-hSUV3 complex-mediated degradation. The knock-down of FASTK
results in the loss of ND6 mRNA and in decreased activity of complex I [125]. FASTKD1 interacts
with Twinkle and co-localizes with mtDNA [126]. Its loss causes ND3 mRNA accumulation and an
increased complex I activity, opposite to the FASTK loss effect. How FASTD1 negatively regulates
complex I activity through the effect on ND3 mRNA is still unknown [126,127]. FASTKD2 is present
in MRGs, where it interacts with the GRSF1 protein. It binds with a defined set of mitochondrial
transcripts including 16S ribosomal RNA and ND6 mRNA [84,125,128]. More recently, FASTKD2 was
found to be part of a pseudouridilation functional module inside the mitochondria along with NGRN
(Neugrin), WB-SCR16, and the Mitochondrial mRNA pseudouridine synthases RPUSD3, RPUSD4, and
TRUB2 [129]. This module is fundamental for the stability of 16S rRNA [129]. The loss of FASTKD2
leads to a decrease in 16S rRNA, an impaired translation process, and the aberrant processing and
expression of ND6 mRNA. Depending on the cell line considered, the depletion of FASTKD2 can cause
either a decrease in the activity of the respiratory complexes or no visible effect [84,128,129].
Of the entire FASTK protein family, FASTKD2 is the only one whose mutations can cause
human syndromes. A homozygous nonsense mutation in the FASTKD2 gene was found to cause
mitochondrial encephalomyopathy associated with developmental delay, hemiplegia, convulsions,
and low cytochrome C oxidase activity in skeletal muscle [124]. Recently, a heterozygous mutation
was reported in a case of adult-onset MELAS (mitochondrial encephalomyopathy, lactic acidosis, and
stroke-like episode)-like syndrome [130]. FASTKD2 has been also implicated as a target for modulating
neurodegeneration and memory loss in ageing and dementia [118]. Furthermore, FASTKD2 has
been also shown to mediate apoptosis in breast and prostate cancers. FASTKD2 is the last target of
the NRIF3/DD1/DIF-1 pro-apoptotic axis, and this pathway was found to mediate the apoptosis in
LNCaP cells.
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FASTKD3 is also required for the correct processing of the transcript, and its silencing leads to an
increased steady-state level and a half-life of ND2, ND3, CYB, CO2, and ATP8/6 mRNAs. It is also
required for COXI protein synthesis and for the proper assembly and activity of the complex IV [131].
FASTKD4 is present overall in the mitochondrial matrix and it binds to the majority of heavy-strand
encoded transcripts. Its depletion leads to decreased levels of ATP8/6, CO1, CO2, MT-CO3, ND3, CYB,
and ND5 mRNAs regulating the stability of these transcripts [127,132]. FASTKD5 is enriched in MRGs
and is required for the processing of some of the non-canonical transcripts. The loss of FASTKD5
results in the accumulation of partially processed primary transcripts such as ATP8/6-CO3, ND5-CYB,
and ribosomal RNAs-CO1 and to an overall decrease in protein translation, suggesting a regulation of
abundance of all mitochondrially encoded RNAs [84]. FASTKD5 was also proposed as a regulator
of adaptation during metabolic stress, oncogenic transformation, and innate immunity through the
association with NLRX1, a member of the Nucleotide-binding Leucine-rich Repeat family receptor
(NLR) usually implicated in the immunity response as a negative regulator of anti-viral signaling [133].
It was demonstrated that the association of NLRX1 with FASTKD5 has a negative impact on the
non-canonical mtRNA transcript processing of mitochondrially encoded proteins belonging to complex
I and IV and consequently on the activity of these complexes [133].
6.4. Processing Regulation by Nucleoid Proteins
Recently, it was proposed that Twinkle and the mitochondrial Single-stranded DNA-binding
protein (mtSSB), two proteins normally associated with nucleoids and mtDNA, could play a role in the
mitochondrial RNA biology. Indeed, both of them were found in the MRGs, and repression of either of
them was demonstrated to alter mtRNA metabolism. In particular, Twinkle depletion leads to the
disruption of MRGs without disturbing RNA expression and processing, while mtSSB loss leads to
RNA processing defects, an accumulation of mtRNA intermediate products, and increased levels of
dsRNA and RNA/DNA hybrids [134].
7. Mitochondrial mRNA Degradation
Once the mRNAs, tRNAs, and rRNAs are used several times for the translation of proteins,
they might be degraded to eliminate aberrant or damaged transcripts. The best characterized protein
complex dedicated to the mt-mRNA degradation in the mitochondrial matrix is the hSUV3/PNPase
complex [85]. hSUV3 and PNPase have been shown to partially co-localize with the MRGs, although
it has been suggested that RNA degradation can take place in specialized foci, called D-foci [83,102].
D-foci, besides containing the degradosome, also localize with newly synthetized mtRNA, similarly to
MRGs, suggesting that a subpopulation of MRGs can participate in the RNA processing of degradation
mediated by the degradosome [85]. Another protein potentially involved in the degradation of mtRNA
is the RNA exonuclease REXO2. This 3′-to-5′ exonuclease acts as a homotetramer and degrades
oligonucleotides in the matrix. As for PNPase, REXO2 seems to have a dual localization: in the
mitochondrial matrix and in the mitochondrial intermembrane space [135]. It was suggested that,
because the degradosome is expected to degrade RNA in small oligo-ribonucleotides, it is possible that
they become a substrate for REXO2 to complete later stages of decay [135].
hSUV3 is an NTP-dependent helicase that has more than one isoform, and at least one of these is
localized in the mitochondrial matrix. This protein is able to unwind different DNA and RNA substrates.
Szczesny et al. suggested that this helicase is involved in the degradation of the damaged mtRNAs and
plays a role in the decay of the properly processed RNA molecules [136–138]. The protein partner acting
with hSUV3 is PNPase, a polynucleotide phosphorylase capable of 3′-to-5′ phosphorolysis and 5′-to-3′
RNA polymerization [139,140]. For its role in RNA degradation, PNPase localizes in the mitochondrial
matrix, but some studies have recently shown the localization of the enzyme in the mitochondrial
intermembrane space [141]. For this multiple localization, PNPase has been attributed to different
processes in RNA metabolism. In the mitochondrial matrix, it takes part in the degradation process of
RNA and in the polyadenilation process, while in the intermembrane space it seems to be involved in
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the import of different RNA species from the cytoplasm [85,141,142]. PNPase co-immunoprecipitated
with SUV3 from mitochondrial cell extracts and foci of exogenously produced hPNPase and SUV3
colocalized with mitochondrial DNA and RNA [85,88]. Furthermore, the knock-down of hPNPase
in HeLa cells resulted in the stabilization of mitochondrial mRNAs [85,143], while the depletion of
hPNPase or SUV3 led to the accumulation of mitochondrial double-stranded RNA [144]. It was also
demonstrated recently that the PNPase/hSUV3 complex is able to interact with GRSF1 to degrade the
non-coding antisense RNAs produced with the transcription process [145].
Pathogenic mutations of the PNPase encoding gene were identified and gave rise to two
different pathologies. Gln387Arg transition leads to severe hypotonia and movement abnormalities
in late infancy, with severe but non-progressive encephalopathy accompanied by elevated plasma
and cerebrospinal-fluid lactate levels [146]. The Glu475Gly transition leads to severe, early onset
hearing impairment in early childhood [147]. It was demonstrated that these mutations affect the
homo-trimerization of PNPase, disturbing the RNA import function of the protein, but the effect on
exoribonuclease activity has not yet been investigated.
REXO2 is the other exoribonuclease present in the intermembrane space and in the mitochondrial
matrix and has a 3′–5′ exonuclease activity specific to small oligomers. It was shown that silencing
REXO2 leads to a disorganized mitochondrial network, a decrease in mtRNA and mtDNA levels, and
an impaired translation process, negatively affecting cell growth [135].
8. Regulation of Mitochondrial RNA Stability and Decay
The regulation of mRNA stability and turnover are fundamental in controlling gene expression
and are usually mediated by protein complexes. The best characterized complex is the LRPPRC/SLIRP,
which prevents the degradation of mtRNAs. LRPPRC is a leucin-rich pentatricopeptide repeat
(PPR)-containing protein that binds RNA and is mainly present in the mitochondrial matrix [148].
The knock-down of LRPPRC in mice results in drastically reduced steady-state levels of mRNAs (but
not of mt-tRNAs or mt-rRNAs), and determining reduced polyadenylation and transcript-processing
defects, and impaired translation [149–153]. LRPPRC is also able to block the action of PNPase that
degrades RNA, while promoting polyadenylation by stimulating the activity of mtPAP [143]. The other
protein that acts in a complex with LRPPRC to stabilize mRNAs is the stem-loop-interacting RNA
binding protein (SLIRP) [154]. The knock-down of one of the two proteins causes a decrease in the
levels of the other, moreover SLIRP alone is not able to have an effect on polyadenylation of the
transcript [143,152]. It has been suggested that LRPPRC is able to stabilize a pool of translationally
inactive mt-mRNAs that are not associated with the ribosome. It has also been suggested that the
LRPPRC/SLIRP complex can bind the mRNA preventing the formation of secondary structures, leaving
the 3′-end available for polyadenylation. This activity could also be involved in the suppression of
PNPase/hSUV3 mt-mRNAs degradation [143,152].
LRPPRC mutations are causative of the Leigh syndrome French Canadian (LSFC) type and was
identified as one of the first nuclear mitochondrial disease genes [155]. The mutation is associated
with a severe autosomal recessive disease characterized by severe COX deficiency, which particularly
affects the liver and brain, and to a lesser extent fibroblasts and skeletal muscle [156]. Patients affected
suffer from a severe neurological disorder characterized by subacute necrotizing encephalopathy,
moderate developmental delay, hypotonia, ataxia, strabismus, opthalmoplegia, optic atrophy, and mild
facial dysmorphia [155]. In patient fibroblasts, LPRRPC mutation leads to a decrease in the mRNA
levels of COI and COIII transcripts and a reduced content of COXI and III proteins explaining the
reduced COX activity of these cells [156,157]. Tissue-specific differences were also described for these
patients, suggesting that different expression levels of LPRRPC and SLIRP are responsible for the
phenotype [158].
LPRRPC has been documented in various tumors, contributing to the apoptosis resistance of human
cancer cells. LRPPRC is abundantly expressed in the side population of lung adenocarcinoma cell lines,
where cancer stem cells are enriched. The expression of this protein was verified in different types
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of tumors such as those associated with lung adenocarcinoma, esophageal squamous cell carcinoma,
endometrial adenocarcinoma, lymphoma, and stomach, colon, and mammary cancers. In all these
cases, LPRRPC was highly expressed, and the knock-down of the protein in lung adenocarcinoma cells
reduced the ability of anti-apoptosis, invasion, and in vitro colony formation of the cells, highlighting
the fundamental role of LPRRPC in tumorigenesis, resistance to apoptosis, and invasion of cancer
cells [159]. LRPPRC has also been identified as an inhibitor of autophagy and mitophagy via interaction
with the mitophagy initiator Parkin. Dysfunctions of LRPPRC are associated with poor prognosis in
ovarian cancer patients. Moreover, LRPPRC overexpression was found in prostate adenocarcinomas
and gastric cancer. Zou and colleagues investigated a possible connection between autophagy inhibition
and LRPPRC involvement in cancer development. It was demonstrated that autophagy stimulates
Parkin translocation to trigger the rupture of the outer membrane of mitochondria and binds to
LRPPRC. The authors showed that the two proteins interact, helping mitochondria to being engulfed
in the autophagosomes for the degradation and demonstrating that LRPPRC functions as a checkpoint
protein that prevents mitochondria from autophagy degradation [160].
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9. Conclusions
The human mitochondrial genome is extremely small compared with the nuclear genome; however,
despite its reduced dimensions, transcription and translation of mitochondrial genes are essential for
cell well-being. Mitochondrial DNA replication and transcription are spatio-temporally regulated to
adapt to the metabolic demand of the cell and are controlled by several factors. In MRGs, both strands
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of mtDNA are transcribed into two polycistronic mtRNA molecules that are processed to release three
different RNA species: tRNA, rRNA, and mRNA. Once formed, these RNAs are further processed to
reach their mature form and to generate mitochondrial polypeptides. Finally, damaged mtRNA has to
be degraded to avoid the formation of an aberrant transcript.
In the last decades, several mitochondrial human pathologies have been associated with a
malfunctioning mtRNA metabolism. However, although many research groups have contributed
to elucidating the molecular details of mitochondrial RNA processing, there are still several open
questions that need to be answered.
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Abbreviations
TFAM Mitochondrial transcription factor A
POLMRT Mitochondrial RNA polymerase
TEFM Mitochondrial transcription elongator factor
mTERF Mitochondrial transcription termination factor
HSP Heavy strand promoter
LSP Light strand promoter
TAS Termination associated sequence
CSB Conserved sequence block
GQP G-quadruplex structures
MOF Males absent on the first
KAT Lysine acetyl transferase
PNPase Polynucleotide phosphorylase
STAT3 Signal transducer and activator of transcriptional protein 3
NRF Nuclear respiratory factor
YY1 Yin yang 1
PGC1 Peroxisome proliferator-activated receptor gamma coactivator 1
PRC PGC-1-related coactivator
mTOR Mammalian target of rapamycin
NF-κB Nuclear Factor Kappa B
HIF1α Hypoxia inducible factor -1α
MRGs Mitochondrial RNA granules
mt-SSU Mitochondrial small subunit
mt-LSU Mitochondrial large subunit
mtPAP Mitochondrial poly-A polymerase
GRSF1 G-rich sequence factor 1
FASTK FAS-activated serine/threonine kinase
NLR Nucleotide-binding Leucine-rich Repeat family receptor
mtSSB Mitochondrial Single-stranded DNA-binding protein
LRPPRC Leucin-rich pentatricopeptide repeat (PPR)-containing
SLIRP Stem-loop-interacting RNA binding protein
References
1. De Vries, R. DNA condensation in bacteria: Interplay between macromolecular crowding and nucleoid
proteins. Biochimie 2010, 92, 1715–1721. [CrossRef]
2. Nass, M.M.; Nass, S. Intramitochondrial Fibers with DNA Characteristics. I. Fixation and electron staining
reactions. J. Cell Biol. 1963, 19, 593–611. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 2221 16 of 23
3. Anderson, S.; Bankier, A.T.; Barrell, B.G.; de Bruijn, M.H.L.; Coulson, A.R.; Drouin, J.; Eperon, I.C.;
Nierlich, D.P.; Roe, B.A.; Sanger, F.; et al. Sequence and organization of the human mitochondrial genome.
Nature 1981, 290, 457–465. [CrossRef]
4. Kvist, L. Paternal Leakage of Mitochondrial DNA in the Great Tit (Parus major). Mol. Biol. Evol. 2003, 20,
243–247. [CrossRef] [PubMed]
5. Ojala, D.; Montoya, J.; Attardi, G. TRNA punctuation model of RNA processing in human mitochondria.
Nature 1981, 290, 470–474. [CrossRef] [PubMed]
6. Iborra, F.J.; Kimura, H.; Cook, P.R.; Hermann, G.; Shaw, J.; Yaffe, M.; Otsuga, D.; Keegan, B.; Brisch, E.;
Thatcher, J.; et al. The functional organization of mitochondrial genomes in human cells. BMC Biol. 2004, 2,
9. [CrossRef]
7. Antonicka, H.; Sasarman, F.; Nishimura, T.; Paupe, V.; Shoubridge, E.A. The mitochondrial RNA-binding
protein GRSF1 localizes to RNA granules and is required for posttranscriptional mitochondrial gene
expression. Cell Metab. 2013, 17, 386–398. [CrossRef]
8. Jourdain, A.A.; Koppen, M.; Wydro, M.; Rodley, C.D.; Lightowlers, R.N.; Chrzanowska-Lightowlers, Z.M.;
Martinou, J.C. GRSF1 regulates RNA processing in mitochondrial RNA granules. Cell Metab. 2013, 17,
399–410. [CrossRef]
9. Masters, B.S.; Stohl, L.L.; Clayton, D.A. Yeast mitochondrial RNA polymerase is homologous to those
encoded by bacteriophages T3 and T7. Cell 1987, 51, 89–99. [CrossRef]
10. Tiranti, V.; Savoia, A.; Forti, F.; D’Apolito, M.F.; Centra, M.; Rocchi, M.; Zeviani, M. Identification of the
gene encoding the human mitochondrial RNA polymerase (h-mtRPOL) by cyberscreening of the Expressed
Sequence Tags database. Hum. Mol. Genet. 1997, 6, 615–625. [CrossRef] [PubMed]
11. Shi, Y.; Dierckx, A.; Wanrooij, P.H.; Wanrooij, S.; Larsson, N.-G.; Wilhelmsson, L.M.; Falkenberg, M.;
Gustafsson, C.M. Mammalian transcription factor A is a core component of the mitochondrial transcription
machinery. Proc. Natl. Acad. Sci. USA 2012, 109, 16510–16515. [CrossRef] [PubMed]
12. Minczuk, M.; He, J.; Duch, A.M.; Ettema, T.J.; Chlebowski, A.; Dzionek, K.; Nijtmans, L.G.J.; Huynen, M.A.;
Holt, I.J. TEFM (c17orf42) is necessary for transcription of human mtDNA. Nucleic Acids Res. 2011, 39,
4284–4299. [CrossRef]
13. Cotney, J.; Wang, Z.; Shadel, G.S. Relative abundance of the human mitochondrial transcription system
and distinct roles for h-mtTFB1 and h-mtTFB2 in mitochondrial biogenesis and gene expression. Nucleic
Acids Res. 2007, 35, 4042–4054. [CrossRef] [PubMed]
14. Falkenberg, M.; Gaspari, M.; Rantanen, A.; Trifunovic, A.; Larsson, N.G.; Gustafsson, C.M. Mitochondrial
transcription factors B1 and B2 activate transcription of human mtDNA. Nat. Genet. 2002, 31, 289–294.
[CrossRef]
15. Agaronyan, K.; Morozov, Y.I.; Anikin, M.; Temiakov, D. Replication-transcription switch in human
mitochondria. Science 2015, 347, 548–551. [CrossRef] [PubMed]
16. Posse, V.; Shahzad, S.; Falkenberg, M.; Hällberg, B.M.; Gustafsson, C.M. TEFM is a potent stimulator of
mitochondrial transcription elongation in vitro. Nucleic Acids Res. 2015, 43, 2615–2624. [CrossRef] [PubMed]
17. Montoya, J.; Christianson, T.; Levens, D.; Rabinowitz, M.; Attardi, G. Identification of initiation sites for
heavy-strand and light-strand transcription in human mitochondrial DNA. Proc. Natl. Acad. Sci. USA 1982,
79, 7195–7199. [CrossRef] [PubMed]
18. Kruse, B.; Narasimhan, N.; Attardi, G. Termination of transcription in human mitochondria: Identification
and purification of a DNA binding protein factor that promotes termination. Cell 1989, 58, 391–397. [CrossRef]
19. Fernandez-Silva, P.; Martinez-Azorin, F.; Micol, V.; Attardi, G. The human mitochondrial transcription
termination factor (mTERF) is a multizipper protein but binds to DNA as a monomer, with evidence pointing
to intramolecular leucine zipper interactions. EMBO J. 1997, 16, 1066–1079. [CrossRef]
20. Wanrooij, P.H.; Uhler, J.P.; Simonsson, T.; Falkenberg, M.; Gustafsson, C.M. G-quadruplex structures in RNA
stimulate mitochondrial transcription termination and primer formation. Proc. Natl. Acad. Sci. USA 2010,
107, 16072–16077. [CrossRef]
21. Nicholls, T.J.; Minczuk, M. In D-loop: 40 years of mitochondrial 7S DNA. Exp. Gerontol. 2014, 56, 175–181.
[CrossRef]
22. Parshin, A.V.; Agaronyan, K.; Anikin, M.; Cramer, P.; Cheung, A.C.M.; Temiakov, D.; Morozov, Y.I. A model
for transcription initiation in human mitochondria. Nucleic Acids Res. 2015, 43, 3726–3735.
Int. J. Mol. Sci. 2019, 20, 2221 17 of 23
23. Shutt, T.E.; Gray, M.W. Homologs of mitochondrial transcription factor B, sparsely distributed within the
eukaryotic radiation, are likely derived from the dimethyladenosine methyltransferase of the mitochondrial
endosymbiont. Mol. Biol. Evol. 2006, 23, 1169–1179. [CrossRef]
24. Stiles, A.R.; Simon, M.T.; Stover, A.; Eftekharian, S.; Khanlou, N.; Wang, H.L.; Magaki, S.; Lee, H.; Partynski, K.;
Dorrani, N.; et al. Mutations in TFAM, encoding mitochondrial transcription factor A, cause neonatal liver
failure associated with mtDNA depletion. Mol. Genet. Metab. 2016, 119, 91–99. [CrossRef]
25. Kang, I.; Chu, C.T.; Kaufman, B.A. The mitochondrial transcription factor TFAM in neurodegeneration:
Emerging evidence and mechanisms. FEBS Lett. 2018, 592, 793–811. [CrossRef]
26. Cramer, P.; Chernev, A.; Graber, J.J.; Urlaub, H.; Schwinghammer, K.; Agaronyan, K.; Parshin, A.V.;
Temiakov, D.; Morozov, Y.I.; Anikin, M.; et al. Mechanism of Transcription Anti-termination in Human
Mitochondria. Cell 2017, 171, 1082–1093.
27. Terzioglu, M.; Ruzzenente, B.; Harmel, J.; Mourier, A.; Jemt, E.; López, M.D.; Kukat, C.; Stewart, J.B.;
Wibom, R.; Meharg, C.; et al. MTERF1 Binds mtDNA to prevent transcriptional interference at the
light-strand promoter but is dispensable for rRNA gene transcription regulation. Cell Metab. 2013, 17,
618–626. [CrossRef]
28. Psarra, A.M.G.; Sekeris, C.E. Steroid and thyroid hormone receptors in mitochondria. IUBMB Life 2008, 60,
210–223. [CrossRef]
29. Morrish, F.; Buroker, N.E.; Ge, M.; Ning, X.H.; Lopez-Guisa, J.; Hockenbery, D.; Portman, M.A. Thyroid
hormone receptor isoforms localize to cardiac mitochondrial matrix with potential for binding to receptor
elements on mtDNA. Mitochondrion 2006, 6, 143–148. [CrossRef]
30. Wrutniak-Cabello, C.; Casas, F.; Cabello, G. Thyroid hormone action: The p43 mitochondrial pathway.
Methods Mole. Biol. 2018, 1801, 163–181.
31. Köhrle, J. Thyroid hormones and derivatives: Endogenous thyroid hormones and their targets. Methods
Mole. Biol. 2018, 1801, 85–104.
32. Wrutniak, C.; Cassar-Malek, I.; Marchal, S.; Rascle, A.; Heusser, S.; Keller, J.M.; Fléchon, J.; Dauça, M.;
Samarut, J.; Ghysdael, J.; et al. A 43-kDa protein related to c-Erb A alpha 1 is located in the mitochondrial
matrix of rat liver. J. Biol. Chem. 1995, 270, 16347–16354. [CrossRef] [PubMed]
33. Lapp, H.E.; Bartlett, A.A.; Hunter, R.G. Stress and glucocorticoid receptor regulation of mitochondrial gene
expression. J. Mol. Endocrinol. 2019, 62, R121–R128. [CrossRef] [PubMed]
34. Scheller, K.; Sekeris, C.E.; Krohne, G.; Hock, R.; Hansen, I.A.; Scheer, U. Localization of glucocorticoid
hormone receptors in mitochondria of human cells. Eur. J. Cell Biol. 2000, 79, 299–307. [CrossRef]
35. Hsieh, Y.C.; Yu, H.P.; Suzuki, T.; Choudhry, M.A.; Schwacha, M.G.; Bland, K.I.; Chaudry, I.H. Upregulation of
mitochondrial respiratory complex IV by estrogen receptor-β is critical for inhibiting mitochondrial apoptotic
signaling and restoring cardiac functions following trauma-hemorrhage. J. Mol. Cell. Cardiol. 2006, 41,
511–521. [CrossRef] [PubMed]
36. Franco, D.G.; Moretti, I.F.; Marie, S.K.N. Mitochondria transcription factor a: A putative target for the effect
of melatonin on U87MG malignant glioma cell line. Molecules 2018, 23, 1129. [CrossRef]
37. Marinov, G.K.; Wang, Y.E.; Chan, D.; Wold, B.J. Evidence for site-specific occupancy of the mitochondrial
genome by nuclear transcription factors. PLoS ONE 2014, 9, e84713. [CrossRef] [PubMed]
38. Chae, S.; Ahn, B.Y.; Byun, K.; Cho, Y.M.; Yu, M.H.; Lee, B.; Hwang, D.; Park, K.S. A systems approach for
decoding mitochondrial retrograde signaling pathways. Sci. Signal. 2013, 6, rs4. [CrossRef]
39. Lambertini, E.; Penolazzi, L.; Morganti, C.; Lisignoli, G.; Zini, N.; Angelozzi, M.; Bonora, M.; Ferroni, L.;
Pinton, P.; Zavan, B.; et al. Osteogenic differentiation of human MSCs: Specific occupancy of the mitochondrial
DNA by NFATc1 transcription factor. Int. J. Biochem. Cell Biol. 2015, 64, 212–219. [CrossRef]
40. Parisi, M.A.; Clayton, D.A. Similarity of human mitochondrial transcription factor 1 to high mobility group
proteins. Science 1991, 252, 965–969. [CrossRef] [PubMed]
41. Fisher, R.P.; Clayton, D.A. Purification and characterization of human mitochondrial transcription factor 1.
Mol. Cell. Biol. 1988, 8, 3496–3509. [CrossRef]
42. Sato, H.; Tachifuji, A.; Tamura, M.; Miyakawa, I. Identification of the YMN-1 antigen protein and biochemical
analyses of protein components in the mitochondrial nucleoid fraction of the yeast Saccharomyces cerevisiae.
Protoplasma 2002, 219, 51–58. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 2221 18 of 23
43. Kaufman, B.A.; Durisic, N.; Mativetsky, J.M.; Costantino, S.; Hancock, M.A.; Grutter, P.; Shoubridge, E.A.
The Mitochondrial Transcription Factor TFAM Coordinates the Assembly of Multiple DNA Molecules into
Nucleoid-like Structures. Mol. Biol. Cell 2007, 18, 3225–3236. [CrossRef] [PubMed]
44. Ghivizzani, S.C.; Madsen, C.S.; Nelen, M.R.; Ammini, C.V.; Hauswirth, W.W. In organello footprint analysis
of human mitochondrial DNA: Human mitochondrial transcription factor A interactions at the origin of
replication. Mol. Cell. Biol. 1994, 14, 7717–7730. [CrossRef]
45. Maniura-Weber, K.; Goffart, S.; Garstka, H.L.; Montoya, J.; Wiesner, R.J. Transient overexpression of
mitochondrial transcription factor A (TFAM) is sufficient to stimulate mitochondrial DNA transcription,
but not sufficient to increase mtDNA copy number in cultured cells. Nucleic Acids Res. 2004, 32, 6015–6027.
[CrossRef] [PubMed]
46. Takamatsu, C.; Umeda, S.; Ohsato, T.; Ohno, T.; Abe, Y.; Fukuoh, A.; Shinagawa, H.; Hamasaki, N.; Kang, D.
Regulation of mitochondrial D-loops by transcription factor A and single-stranded DNA-binding protein.
EMBO Rep. 2002, 3, 451–456. [CrossRef]
47. Alam, T.I.; Kanki, T.; Muta, T.; Ukaji, K.; Abe, Y.; Nakayama, H.; Takio, K.; Hamasaki, N.; Kang, D. Human
mitochondrial DNA is packaged with TFAM. Nucleic Acids Res. 2003, 31, 1640–1645. [CrossRef] [PubMed]
48. Ekstrand, M.I.; Falkenberg, M.; Rantanen, A.; Park, C.B.; Gaspari, M.; Hultenby, K.; Rustin, P.;
Gustafsson, C.M.; Larsson, N.G. Mitochondrial transcription factor A regulates mtDNA copy number
in mammals. Hum. Mol. Genet. 2004, 13, 935–944. [CrossRef] [PubMed]
49. Uchida, A.; Murugesapillai, D.; Kastner, M.; Wang, Y.; Lodeiro, M.F.; Prabhakar, S.; Oliver, G.V.; Arnold, J.J.;
Maher, L.J.; Williams, M.C.; et al. Unexpected sequences and structures of mtDNA required for efficient
transcription from the first heavy-strand promoter. Elife 2017, 6, e27283. [CrossRef]
50. Lyonnais, S.; Tarrés-Soler, A.; Rubio-Cosials, A.; Cuppari, A.; Brito, R.; Jaumot, J.; Gargallo, R.; Vilaseca, M.;
Silva, C.; Granzhan, A.; et al. The human mitochondrial transcription factor A is a versatile G-quadruplex
binding protein. Sci. Rep. 2017, 7, 43992. [CrossRef]
51. Blumberg, A.; Danko, C.G.; Kundaje, A.; Mishmar, D. A common pattern of DNase I footprinting throughout
the human mtDNA unveils clues for a chromatin-like organization. Genome Res. 2018, 28, 1158–1168.
[CrossRef]
52. Rebelo-Guiomar, P.; Powell, C.A.; Van Haute, L.; Minczuk, M. The mammalian mitochondrial
epitranscriptome. Biochim. Biophys. Acta Gene Regul. Mech. 2019, 1862, 429–446. [CrossRef]
53. Marom, S.; Blumberg, A.; Kundaje, A.; Mishmar, D. mtDNA Chromatin-like Organization Is Gradually
Established during Mammalian Embryogenesis. iScience 2019, 12, 141–151. [CrossRef] [PubMed]
54. Gu, W.; Szauter, P.; Lucchesi, J.C. Targeting of MOF, a putative histone acetyl Transferase, to the X chromosome
of Drosophila melanogaster. Dev. Genet. 1998, 22, 56–64. [CrossRef]
55. Hilfiker, A.; Hilfiker-Kleiner, D.; Pannuti, A.; Lucchesi, J.C. mof, a putative acetyl transferase gene related to
the Tip60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in
Drosophila. EMBO J. 1997, 16, 2054–2060. [CrossRef] [PubMed]
56. Taipale, M.; Rea, S.; Richter, K.; Vilar, A.; Lichter, P.; Imhof, A.; Akhtar, A. hMOF Histone Acetyltransferase Is
Required for Histone H4 Lysine 16 Acetylation in Mammalian Cells. Mol. Cell. Biol. 2005, 25, 6798–6810.
[CrossRef] [PubMed]
57. Chatterjee, A.; Mårtensson, C.U.; Avilov, S.; Böttinger, L.; Lucci, J.; Pfanner, N.; Kretz, O.; Eimer, S.; Stehle, T.;
Becker, T.; et al. MOF Acetyl Transferase Regulates Transcription and Respiration in Mitochondria. Cell 2016,
167, 722–738.e23. [CrossRef] [PubMed]
58. Macias, E.; Rao, D.; Carbajal, S.; Kiguchi, K.; Digiovanni, J. Stat3 binds to mtDNA and regulates mitochondrial
gene expression in keratinocytes. J. Investig. Dermatol. 2014, 134, 1971–1980. [CrossRef] [PubMed]
59. Baldelli, S.; Pagliei, B.; Aquilano, K.; Rotilio, G.; Vigilanza, P.; Ciriolo, M.R. Peroxisome Proliferator-activated
Receptor γ Co-activator 1α (PGC-1α) and Sirtuin 1 (SIRT1) Reside in Mitochondria. J. Biol. Chem. 2010, 285,
21590–21599.
60. Mishra, M.; Kowluru, R.A. Epigenetic modification of mitochondrial DNA in the development of diabetic
retinopathy. Investig. Ophthalmol. Vis. Sci. 2015, 56, 5133–5142. [CrossRef]
61. Bandiera, S.; Matégot, R.; Girard, M.; Demongeot, J.; Henrion-Caude, A. MitomiRs delineating the intracellular
localization of microRNAs at mitochondria. Free Radic. Biol. Med. 2013, 64, 12–19. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 2221 19 of 23
62. Shepherd, D.L.; Hathaway, Q.A.; Pinti, M.V.; Nichols, C.E.; Durr, A.J.; Sreekumar, S.; Hughes, K.M.; Stine, S.M.;
Martinez, I.; Hollander, J.M. Exploring the mitochondrial microRNA import pathway through Polynucleotide
Phosphorylase (PNPase). J. Mol. Cell. Cardiol. 2017, 110, 15–25. [CrossRef] [PubMed]
63. Barrey, E.; Saint-Auret, G.; Bonnamy, B.; Damas, D.; Boyer, O.; Gidrol, X. Pre-microRNA and Mature
microRNA in Human Mitochondria. PLoS ONE 2011, 6, e20220. [CrossRef] [PubMed]
64. Shinde, S.; Bhadra, U. A Complex Genome-MicroRNA Interplay in Human Mitochondria. Biomed Res. Int.
2015, 2015, 206382. [CrossRef] [PubMed]
65. Bandiera, S.; Rüberg, S.; Girard, M.; Cagnard, N.; Hanein, S.; Chrétien, D.; Munnich, A.; Lyonnet, S.;
Henrion-Caude, A. Nuclear outsourcing of RNA interference components to human mitochondria. PLoS ONE
2011, 6, e20746. [CrossRef] [PubMed]
66. Tannous, B.A.; Lin, X.; Li, J.; Fan, S.; Ferrone, S.; Lv, X.; Cai, L.; Wang, X.; Sun, S.; Zhang, H.;
et al. Mitochondrial miRNA determines chemoresistance by reprogramming metabolism and regulating
mitochondrial transcription. Cancer Res. 2019, 79, 1069–1084.
67. Kelly, D.P.; Scarpulla, R.C. Transcriptional regulatory circuits controlling mitochondrial biogenesis and
function. Genes Dev. 2004, 18, 357–368. [CrossRef] [PubMed]
68. Murakami, T.; Shimomura, Y.; Yoshimura, A.; Sokabe, M.; Fujitsuka, N. Induction of nuclear respiratory
factor-1 expression by an acute bout of exercise in rat muscle. Biochim. Biophys. Acta Gen. Subj. 1998, 1381,
113–122. [CrossRef]
69. Suliman, H.B.; Carraway, M.S.; Welty-Wolf, K.E.; Whorton, A.R.; Piantadosi, C.A. Lipopolysaccharide
Stimulates Mitochondrial Biogenesis via Activation of Nuclear Respiratory Factor-1. J. Biol. Chem. 2003, 278,
41510–41518. [CrossRef]
70. Gleyzer, N.; Vercauteren, K.; Scarpulla, R.C. Control of Mitochondrial Transcription Specificity Factors
(TFB1M and TFB2M) by Nuclear Respiratory Factors (NRF-1 and NRF-2) and PGC-1 Family Coactivators.
Mol. Cell. Biol. 2005, 25, 1354–1366. [CrossRef]
71. Scarpulla, R.C.; Vega, R.B.; Kelly, D.P. Transcriptional integration of mitochondrial biogenesis. Trends
Endocrinol. Metab. 2012, 23, 459–466. [CrossRef]
72. Kim, J.; Guan, K.L. mTOR as a central hub of nutrient signalling and cell growth. Nat. Cell Biol. 2019, 21,
63–71. [CrossRef] [PubMed]
73. Arlow, D.H.; Vazquez, F.; Mootha, V.K.; Rodgers, J.T.; Puigserver, P.; Cunningham, J.T. mTOR controls
mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex. Nature 2007, 450, 736–740.
74. Poletto, M.; Legrand, A.J.; Fletcher, S.C.; Dianov, G.L. P53 coordinates base excision repair to prevent genomic
instability. Nucleic Acids Res. 2016, 44, 3165–3175. [CrossRef]
75. Vaseva, A.V.; Marchenko, N.D.; Ji, K.; Tsirka, S.E.; Holzmann, S.; Moll, U.M. P53 opens the mitochondrial
permeability transition pore to trigger necrosis. Cell 2012, 149, 1536–1548. [CrossRef]
76. Lebedeva, M.A.; Eaton, J.S.; Shadel, G.S. Loss of p53 causes mitochondrial DNA depletion and altered
mitochondrial reactive oxygen species homeostasis. Biochim. Biophys. Acta Bioenerg. 2009, 1787, 328–334.
[CrossRef] [PubMed]
77. Johnson, R.F.; Witzel, I.I.; Perkins, N.D. p53-dependent regulation of mitochondrial energy production by the
RelA subunit of NF-κB. Cancer Res. 2011, 71, 5588–5597. [CrossRef]
78. Li, H.S.; Zhou, Y.N.; Li, L.; Li, S.F.; Long, D.; Chen, X.L.; Zhang, J.B.; Feng, L.; Li, Y.P. HIF-1α protects against
oxidative stress by directly targeting mitochondria. Redox Biol. 2019, in press. [CrossRef]
79. Stuart, J.M.; Segal, E.; Koller, D.; Kim, S.K. A gene-coexpression network for global discovery of conserved
genetic modules. Science 2003, 302, 249–255. [CrossRef]
80. Lee, H.K.; Hsu, A.K.; Sajdak, J.; Qin, J.; Pavlidis, P. Coexpresion analysis of human genes across many
microarray data sets. Genome Res. 2004, 14, 1085–1094. [CrossRef] [PubMed]
81. Van Waveren, C.; Moraes, C.T. Transcriptional co-expression and co-regulation of genes coding for components
of the oxidative phosphorylation system. BMC Genom. 2008, 9, 18. [CrossRef]
82. Mai, N.; Chrzanowska-Lightowlers, Z.M.A.; Lightowlers, R.N. The process of mammalian mitochondrial
protein synthesis. Cell Tissue Res. 2016, 367, 5–20. [CrossRef] [PubMed]
83. Pearce, S.F.; Rebelo-Guiomar, P.; D’Souza, A.R.; Powell, C.A.; Van Haute, L.; Minczuk, M. Regulation of
Mammalian Mitochondrial Gene Expression: Recent Advances. Trends Biochem. Sci. 2017, 9, 323–337.
[CrossRef]
Int. J. Mol. Sci. 2019, 20, 2221 20 of 23
84. Antonicka, H.; Shoubridge, E.A. Mitochondrial RNA Granules Are Centers for Posttranscriptional RNA
Processing and Ribosome Biogenesis. Cell Rep. 2015, 10, 920–932. [CrossRef]
85. Borowski, L.S.; Dziembowski, A.; Hejnowicz, M.S.; Stepien, P.P.; Szczesny, R.J. Human mitochondrial RNA
decay mediated by PNPase-hSuv3 complex takes place in distinct foci. Nucleic Acids Res. 2013, 41, 1223–1240.
[CrossRef] [PubMed]
86. Tu, Y.T.; Barrientos, A. The Human Mitochondrial DEAD-Box Protein DDX28 Resides in RNA Granules and
Functions in Mitoribosome Assembly. Cell Rep. 2015, 10, 854–864. [CrossRef]
87. Barrientos, A. Mitochondriolus: Assembling mitoribosomes. Oncotarget 2015, 6, 16800. [CrossRef]
88. Szczesny, R.J.; Borowski, L.S.; Brzezniak, L.K.; Dmochowska, A.; Gewartowski, K.; Bartnik, E.; Stepien, P.P.
Human mitochondrial RNA turnover caught in flagranti: Involvement of hSuv3p helicase in RNA surveillance.
Nucleic Acids Res. 2009, 38, 279–298. [CrossRef]
89. Lee, K.W.; Okot-Kotber, C.; La Comb, J.F.; Bogenhagen, D.F. Mitochondrial ribosomal RNA (rRNA)
methyltransferase family members are positioned to modify nascent rRNA in foci near the mitochondrial
DNA nucleoid. J. Biol. Chem. 2013, 288, 31386–31399. [CrossRef]
90. Holzmann, J.; Frank, P.; Löffler, E.; Bennett, K.L.; Gerner, C.; Rossmanith, W. RNase P without RNA:
Identification and Functional Reconstitution of the Human Mitochondrial tRNA Processing Enzyme. Cell
2008, 135, 462–474. [CrossRef] [PubMed]
91. Yang, S.Y.; He, X.Y.; Schulz, H. Multiple functions of type 10 17β-hydroxysteroid dehydrogenase. Trends
Endocrinol. Metab. 2005, 16, 167–175. [CrossRef] [PubMed]
92. Vilardo, E.; Nachbagauer, C.; Buzet, A.; Taschner, A.; Holzmann, J.; Rossmanith, W. A subcomplex of human
mitochondrial RNase P is a bifunctional methyltransferase-extensive moonlighting in mitochondrial tRNA
biogenesis. Nucleic Acids Res. 2012, 40, 11583–11593. [CrossRef]
93. Rossmanith, W.; Holzmann, J. Processing mitochondrial (t)RNAs: New enzyme, old job. Cell Cycle 2009, 8,
1650–1653. [CrossRef]
94. Lopez Sanchez, M.I.G.; Mercer, T.R.; Davies, S.M.K.; Shearwood, A.-M.J.; Nygård, K.K.A.; Richman, T.R.;
Mattick, J.S.; Rackham, O.; Filipovska, A. RNA processing in human mitochondria. Cell Cycle 2011, 10,
2904–2916. [CrossRef]
95. Boczonadi, V.; Ricci, G.; Horvath, R. Mitochondrial DNA transcription and translation: Clinical syndromes.
Essays Biochem. 2018, 62, 321–340. [CrossRef]
96. Metodiev, M.D.; Thompson, K.; Alston, C.L.; Morris, A.A.M.; He, L.; Assouline, Z.; Rio, M.; Bahi-Buisson, N.;
Pyle, A.; Griffin, H.; et al. Recessive Mutations in TRMT10C Cause Defects in Mitochondrial RNA Processing
and Multiple Respiratory Chain Deficiencies. Am. J. Hum. Genet. 2016, 98, 993–1000; Erratum in 2016, 99, 246.
[CrossRef]
97. Falk, M.J.; Gai, X.; Shigematsu, M.; Vilardo, E.; Takase, R.; McCormick, E.; Christian, T.; Place, E.; Pierce, E.A.;
Consugar, M.; et al. A novel HSD17B10 mutation impairing the activities of the mitochondrial Rnase P
complex causes X-linked intractable epilepsy and neurodevelopmental regression. RNA Biol. 2016, 13,
477–485. [CrossRef] [PubMed]
98. Rossmanith, W. Localization of human RNase Z isoforms: Dual nuclear/mitochondrial targeting of the
ELAC2 gene product by alternative translation initiation. PLoS ONE 2011, 6, e19152. [CrossRef]
99. Brzezniak, L.K.; Bijata, M.; Szczesny, R.J.; Stepien, P.P. Involvement of human ELAC2 gene product in 3′ end
processing of mitochondrial tRNAs. RNA Biol. 2011, 8, 616–626. [CrossRef]
100. Shinwari, Z.M.A.; Almesned, A.; Alakhfash, A.; Al-Rashdan, A.M.; Faqeih, E.; Al-Humaidi, Z.; Alomrani, A.;
Alghamdi, M.; Colak, D.; Alwadai, A.; et al. The Phenotype and Outcome of Infantile Cardiomyopathy
Caused by a Homozygous ELAC2 Mutation. Cardiology 2017, 137, 188–192. [CrossRef] [PubMed]
101. Rackham, O.; Davies, S.M.K.; Shearwood, A.M.J.; Hamilton, K.L.; Whelan, J.; Filipovska, A. Pentatricopeptide
repeat domain protein 1 lowers the levels of mitochondrial leucine tRNAs in cells. Nucleic Acids Res. 2009,
37, 5859–5867. [CrossRef]
102. Van Haute, L.; Pearce, S.F.; Powell, C.A.; D’Souza, A.R.; Nicholls, T.J.; Minczuk, M. Mitochondrial transcript
maturation and its disorders. J. Inherit. Metab. Dis. 2015, 38, 655–680. [CrossRef] [PubMed]
103. Brown, A.; Amunts, A.; Bai, X.-C.; Sugimoto, Y.; Edwards, P.C.; Murshudov, G.; Scheres, S.H.W.;
Ramakrishnan, V. Structure of the large ribosomal subunit from human mitochondria. Science 2014,
346, 718–722. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 2221 21 of 23
104. Greber, B.J.; Bieri, P.; Leibundgut, M.; Leitner, A.; Aebersold, R.; Boehringer, D.; Ban, N. The complete
structure of the 55. Nature 2014, 348, 303–308.
105. Kaushal, P.S.; Sharma, M.R.; Booth, T.M.; Haque, E.M.; Tung, C.-S.; Sanbonmatsu, K.Y.; Spremulli, L.L.;
Agrawal, R.K. Cryo-EM structure of the small subunit of the mammalian mitochondrial ribosome. Proc. Natl.
Acad. Sci. USA 2014, 111, 7284–7289. [CrossRef]
106. Amunts, A.; Brown, A.; Toots, J.; Scheres, S.H.W.; Ramakrishnan, V. The structure of the human mitochondrial
ribosome. Science 2015, 348, 95–98. [CrossRef]
107. Decatur, W.A.; Fournier, M.J. rRNA modifications and ribosome function. Trends Biochem. Sci. 2002, 27,
344–351. [CrossRef]
108. Piekna-Przybylska, D.D.; Decatur, W.A.; Fournier, M.J. The 3D rRNA modification maps database:
With interactive tools for ribosome analysis. Nucleic Acids Res. 2008, 36, D178–D183. [CrossRef]
109. Temperley, R.J.; Wydro, M.; Lightowlers, R.N.; Chrzanowska-Lightowlers, Z.M. Human mitochondrial
mRNAs-like members of all families, similar but different. Biochim. Biophys. Acta Bioenerg. 2010, 1797,
1081–1085. [CrossRef]
110. Tomecki, R.; Dmochowska, A.; Gewartowski, K.; Dziembowski, A.; Stepien, P.P. Identification of a novel
human nuclear-encoded mitochondrial poly(A) polymerase. Nucleic Acids Res. 2004, 32, 6001–6014.
[CrossRef]
111. Nagaike, T.; Suzuki, T.; Katoh, T.; Ueda, T. Human mitochondrial mRNAs are stabilized with polyadenylation
regulated by mitochondria-specific poly(A) polymerase and polynucleotide phosphorylase. J. Biol. Chem.
2005, 280, 19721–19727. [CrossRef]
112. Bai, Y.; Srivastava, S.K.; Chang, J.H.; Manley, J.L.; Tong, L. Structural Basis for Dimerization and Activity of
Human PAPD1, a Noncanonical Poly(A) Polymerase. Mol. Cell 2011, 41, 311–320. [CrossRef] [PubMed]
113. Wilson, W.C.; Hornig-Do, H.T.; Bruni, F.; Chang, J.H.; Jourdain, A.A.; Martinou, J.C.; Falkenberg, M.;
Spåhr, H.; Larsson, N.G.; Lewis, R.J.; et al. A human mitochondrial poly(A) polymerase mutation reveals the
complexities of post-transcriptional mitochondrial gene expression. Hum. Mol. Genet. 2014, 23, 6345–6355.
[CrossRef] [PubMed]
114. Rorbach, J.; Bobrowicz, A.; Pearce, S.; Minczuk, M. Polyadenylation in bacteria and organelles. Methods
Mol. Biol. 2014, 1125, 211–227. [PubMed]
115. Rorbach, J.; Nicholls, T.J.J.; Minczuk, M. PDE12 removes mitochondrial RNA poly(A) tails and controls
translation in human mitochondria. Nucleic Acids Res. 2011, 39, 7750–7763. [CrossRef]
116. Wydro, M.; Bobrowicz, A.; Temperley, R.J.; Lightowlers, R.N.; Chrzanowska-Lightowlers, Z.M. Targeting of
the cytosolic poly(A) binding protein PABPC1 to mitochondria causes mitochondrial translation inhibition.
Nucleic Acids Res. 2010, 38, 3732–3742. [CrossRef] [PubMed]
117. Rorbach, J.; Minczuk, M. The post-transcriptional life of mammalian mitochondrial RNA. Biochem. J. 2012,
444, 357–373. [CrossRef] [PubMed]
118. Crosby, A.H.; Patel, H.; Chioza, B.A.; Proukakis, C.; Gurtz, K.; Patton, M.A.; Sharifi, R.; Harlalka, G.;
Simpson, M.A.; Dick, K.; et al. Defective mitochondrial mRNA maturation is associated with spastic ataxia.
Am. J. Hum. Genet. 2010, 87, 655–660. [CrossRef] [PubMed]
119. Poulsen, J.B.; Andersen, K.R.; Kjær, K.H.; Durand, F.; Faou, P.; Vestergaard, A.L.; Talbo, G.H.; Hoogenraad, N.;
Brodersen, D.E.; Justesen, J.; et al. Human 2′-phosphodiesterase localizes to the mitochondrial matrix with a
putative function in mitochondrial RNA turnover. Nucleic Acids Res. 2011, 39, 3754–3770. [CrossRef]
120. Cahová, H.; Winz, M.L.; Höfer, K.; Nübel, G.; Jäschke, A. NAD captureSeq indicates NAD as a bacterial cap
for a subset of regulatory RNAs. Nature 2015, 519, 374–377. [CrossRef] [PubMed]
121. Kiledjian, M. Eukaryotic RNA 5′-End NAD+ Capping and DeNADding. Trends Cell Biol. 2018, 28, 454–464.
[CrossRef] [PubMed]
122. Rossetti, G.; Hool, L.C.; Rackham, O.; Viola, H.M.; Richman, T.R.; Perks, K.; Kuznetsova, I.; Shearwood, A.J.;
Ermer, J.A.; Filipovska, A.; et al. Concerted regulation of mitochondrial and nuclear non-coding RNAs by a
dual-targeted RNase Z. EMBO Rep. 2018, 19, e46198.
123. Julius, C.; Riaz-Bradley, A.; Yuzenkova, Y. RNA capping by mitochondrial and multi-subunit RNA
polymerases. Transcription 2018, 9, 292–297. [CrossRef] [PubMed]
124. Popow, J.; de la Fuente, M.A.; Simarro, M.; Jourdain, A.A.; Martinou, J.-C.; Anderson, P. The FASTK family
of proteins: Emerging regulators of mitochondrial RNA biology. Nucleic Acids Res. 2017, 45, 10941–10947.
Int. J. Mol. Sci. 2019, 20, 2221 22 of 23
125. Rodley, C.D.; Simarro, M.; Jourdain, A.A.; Koppen, M.; Martinou, J.-C.; Maundrell, K.; Guaras, A.M.;
Enriquez, J.A.; Gueguen, N.; Anderson, P.; et al. A Mitochondria-Specific Isoform of FASTK Is Present in
Mitochondrial RNA Granules and Regulates Gene Expression and Function. Cell Rep. 2015, 10, 1110–1121.
126. Deerinck, T.J.; Han, S.; Ellisman, M.H.; Carr, S.A.; Svinkina, T.; Ting, A.Y.; Udeshi, N.D. Proximity Biotinylation
as a Method for Mapping Proteins Associated with mtDNA in Living Cells. Cell Chem. Biol. 2017, 24, 404–414.
127. Thore, S.; Maundrell, K.; Martinou, J.-C.; Jourdain, A.A.; Boehm, E.; Zaganelli, S. FASTKD1 and FASTKD4
have opposite effects on expression of specific mitochondrial RNAs, depending upon their endonuclease-like
RAP domain. Nucleic Acids Res. 2017, 45, 6135–6146.
128. Popow, J.; Alleaume, A.-M.; Curk, T.; Schwarzl, T.; Sauer, S.; Hentze, M.W. FASTKD2 is an RNA-binding
protein required for mitochondrial RNA processing and translation. RNA 2015, 21, 1873–1884. [CrossRef]
[PubMed]
129. Lin, Z.; Kleinman, C.L.; Gingras, A.; Shoubridge, E.A.; Choquet, K.; Antonicka, H. A pseudouridine synthase
module is essential for mitochondrial protein synthesis and cell viability. EMBO Rep. 2016, 18, 28–38.
130. Yoo, D.H.; Choi, Y.C.; Nam, D.E.; Choi, S.S.; Kim, J.W.; Choi, B.O.; Chung, K.W. Identification of FASTKD2
compound heterozygous mutations as the underlying cause of autosomal recessive MELAS-like syndrome.
Mitochondrion 2017, 35, 54–58. [CrossRef] [PubMed]
131. Boehm, E.; Orduña, A.; García-Consuegra, I.; Jourdain, A.A.; Martinou, J.-C.; Delmiro Magdalena, A.;
Simarro, M.; Martín, M.A.; De la Fuente, M.A.; Zornoza, M.; et al. Role of FAST Kinase Domains 3 (FASTKD3)
in Post-transcriptional Regulation of Mitochondrial Gene Expression. J. Biol. Chem. 2016, 291, 25877–25887.
[CrossRef] [PubMed]
132. Wolf, A.R.; Mootha, V.K. Functional Genomic Analysis of Human Mitochondrial RNA Processing. Cell Rep.
2014, 7, 918–931. [CrossRef]
133. Singh, K.; Sripada, L.; Lipatova, A.; Roy, M.; Prajapati, P.; Gohel, D.; Bhatelia, K.; Chumakov, P.M.; Singh, R.
NLRX1 resides in mitochondrial RNA granules and regulates mitochondrial RNA processing and bioenergetic
adaptation. Biochim. Biophys. Acta Mol. Cell Res. 2018, 1865, 1260–1276. [CrossRef] [PubMed]
134. Chakraborty, A.; Tarrés-Solé, A.; Solà, M.; van Esveld, S.L.; Spelbrink, J.N.; Hensen, F.; Potter, A. Mitochondrial
RNA granules are critically dependent on mtDNA replication factors Twinkle and mtSSB. Nucleic Acids Res.
2019, 47, 3680–3698.
135. Bruni, F.; Gramegna, P.; Oliveira, J.M.A.; Lightowlers, R.N.; Chrzanowska-Lightowlers, Z.M.A. REXO2 Is an
Oligoribonuclease Active in Human Mitochondria. PLoS ONE 2013, 8, e64670. [CrossRef]
136. Minczuk, M.; Lilpop, J.; Boros, J.; Stepien, P.P. The 5′ region of the human hSUV3 gene encoding mitochondrial
DNA and RNA helicase: Promoter characterization and alternative pre-mRNA splicing. Biochim. Biophys.
Acta Gene Struct. Expr. 2005, 1729, 81–87. [CrossRef]
137. Szczesny, R.J.; Obriot, H.; Paczkowska, A.; Jedrzejczak, R.; Dmochowska, A.; Bartnik, E.; Formstecher, P.;
Polakowska, R.; Stepien, P.P. Down-regulation of human RNA/DNA helicase SUV3 induces apoptosis by a
caspase- and AIF-dependent pathway. Biol. Cell 2007, 99, 323–332. [CrossRef]
138. Kazak, L.; Reyes, A.; Duncan, A.L.; Rorbach, J.; Wood, S.R.; Brea-Calvo, G.; Gammage, P.A.; Robinson, A.J.;
Minczuk, M.; Holt, I.J. Alternative translation initiation augments the human mitochondrial proteome.
Nucleic Acids Res. 2013, 41, 2354–2369. [CrossRef] [PubMed]
139. Wang, D.D.H.; Shu, Z.; Lieser, S.A.; Chen, P.L.; Lee, W.H. Human mitochondrial SUV3 and polynucleotide
phosphorylase form a 330-kDa heteropentamer to cooperatively degradedouble-stranded RNA with a
3′-to-5′ directionality. J. Biol. Chem. 2009, 284, 20812–20821. [CrossRef]
140. Cameron, T.A.; Matz, L.M.; De Lay, N.R. Polynucleotide phosphorylase: Not merely an RNase but a pivotal
post-transcriptional regulator. PLoS Genet. 2018, 14, e1007654. [CrossRef] [PubMed]
141. Chen, H.-W.; Rainey, R.N.; Balatoni, C.E.; Dawson, D.W.; Troke, J.J.; Wasiak, S.; Hong, J.S.; McBride, H.M.;
Koehler, C.M.; Teitell, M.A.; et al. Mammalian Polynucleotide Phosphorylase Is an Intermembrane Space
RNase That Maintains Mitochondrial Homeostasis. Mol. Cell. Biol. 2006, 26, 8475–8487. [CrossRef]
142. Slomovic, S.; Schuster, G. Stable PNPase RNAi silencing: Its effect on the processing and adenylation of
human mitochondrial RNA. RNA 2008, 14, 310–323. [CrossRef]
143. Chujo, T.; Ohira, T.; Sakaguchi, Y.; Goshima, N.; Nomura, N.; Nagao, A.; Suzuki, T. LRPPRC/SLIRP suppresses
PNPase-mediated mRNA decay and promotes polyadenylation in human mitochondria. Nucleic Acids Res.
2012, 40, 8033–8047. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 2221 23 of 23
144. Borowski, L.S.; Dhir, A.; Jimenez, L.; Nojima, T.; Rice, G.I.; Rehwinkel, J.; Tamby, C.; Munnich, A.;
de Almeida, C.R.; Proudfoot, N.J.; et al. Mitochondrial double-stranded RNA triggers antiviral signalling in
humans. Nature 2018, 560, 238–242.
145. Pietras, Z.; Wojcik, M.A.; Borowski, L.S.; Szewczyk, M.; Kulinski, T.M.; Cysewski, D.; Stepien, P.P.;
Dziembowski, A.; Szczesny, R.J. Controlling the mitochondrial antisense–role of the SUV3-PNPase complex
and its co-factor GRSF1 in mitochondrial RNA surveillance. Mol. Cell. Oncol. 2018, 5, e1516452. [CrossRef]
146. Vedrenne, V.; Gowher, A.; De Lonlay, P.; Nitschke, P.; Serre, V.; Boddaert, N.; Altuzarra, C.; Mager-Heckel, A.M.;
Chretien, F.; Entelis, N.; et al. Mutation in PNPT1, which encodes a polyribonucleotide nucleotidyltransferase,
impairs RNA import into mitochondria and causes respiratory-chain deficiency. Am. J. Hum. Genet. 2012, 91,
912–918. [CrossRef]
147. Von Ameln, S.; Wang, G.; Boulouiz, R.; Rutherford, M.A.; Smith, G.M.; Li, Y.; Pogoda, H.M.; Nürnberg, G.;
Stiller, B.; Volk, A.E.; et al. A mutation in PNPT1, encoding mitochondrial-RNA-import protein PNPase,
causes hereditary hearing loss. Am. J. Hum. Genet. 2012, 91, 919–927. [CrossRef]
148. Sterky, F.H.; Ruzzenente, B.; Gustafsson, C.M.; Samuelsson, T.; Larsson, N.G. LRPPRC is a mitochondrial
matrix protein that is conserved in metazoans. Biochem. Biophys. Res. Commun. 2010, 398, 759–764. [CrossRef]
149. Gohil, V.M.; Nilsson, R.; Belcher-Timme, C.A.; Luo, B.; Root, D.E.; Mootha, V.K. Mitochondrial and nuclear
genomic responses to loss of LRPPRC expression. J. Biol. Chem. 2010, 285, 13742–13747. [CrossRef]
150. Sasarman, F.; Brunel-Guitton, C.; Antonicka, H.; Wai, T.; Shoubridge, E.A. LRPPRC and SLIRP Interact in a
Ribonucleoprotein Complex That Regulates Posttranscriptional Gene Expression in Mitochondria. Mol. Biol.
Cell 2010, 21, 1315–1323. [CrossRef]
151. Sondheimer, N.; Fang, J.-K.; Polyak, E.; Falk, M.J.; Avadhani, N.G. Leucine-Rich Pentatricopeptide-Repeat
Containing Protein Regulates Mitochondrial Transcription. Biochemistry 2010, 49, 7467–7473. [CrossRef]
152. Ruzzenente, B.; Metodiev, M.D.; Wredenberg, A.; Bratic, A.; Park, C.B.; Cámara, Y.; Milenkovic, D.;
Zickermann, V.; Wibom, R.; Hultenby, K.; et al. LRPPRC is necessary for polyadenylation and coordination
of translation of mitochondrial mRNAs. EMBO J. 2012, 31, 443–456. [CrossRef]
153. Mourier, A.; Ruzzenente, B.; Brandt, T.; Kühlbrandt, W.; Larsson, N.G. Loss of LRPPRC causes ATP synthase
deficiency. Hum. Mol. Genet. 2014, 23, 2580–2592. [CrossRef]
154. Baughman, J.M.; Nilsson, R.; Gohil, V.M.; Arlow, D.H.; Gauhar, Z.; Mootha, V.K. A computational screen for
regulators of oxidative phosphorylation implicates SLIRP in mitochondrial RNA homeostasis. PLoS Genet.
2009, 5, e1000590. [CrossRef] [PubMed]
155. Morin, C.; Mitchell, G.; Larochelle, J.; Lambert, M.; Ogier, H.; Robinson, B.H.; De Braekeleer, M. Clinical,
metabolic, and genetic aspects of cytochrome C oxidase deficiency in Saguenay-Lac-Saint-Jean. Am. J. Hum.
Genet. 1993, 53, 488–496.
156. Merante, F.; Petrova-Benedict, R.; MacKay, N.; Mitchell, G.; Lambert, M.; Morin, C.; De Braekeleer, M.;
Laframboise, R.; Gagné, R.; Robinson, B.H. A biochemically distinct form of cytochrome oxidase (COX)
deficiency in the Saguenay-Lac-Saint-Jean region of Quebec. Am. J. Hum. Genet. 1993, 53, 481–487.
157. XU, F.; MORIN, C.; MITCHELL, G.; ACKERLEY, C.; ROBINSON, B.H. The role of the LRPPRC (leucine-rich
pentatricopeptide repeat cassette) gene in cytochrome oxidase assembly: Mutation causes lowered levels of
COX (cytochrome c oxidase) I and COX III mRNA. Biochem. J. 2004, 382, 331–336. [CrossRef] [PubMed]
158. Sasarman, F.; Nishimura, T.; Antonicka, H.; Weraarpachai, W.; Shoubridge, E.A.; Allen, B.; Burelle, Y.;
Charron, G.; Coderre, L.; DesRosiers, C.; et al. Tissue-specific responses to the LRPPRC founder mutation in
French Canadian Leigh Syndrome. Hum. Mol. Genet. 2015, 24, 480–491. [CrossRef]
159. Morii, E.; Mamat, S.; Luo, W.; Aozasa, K.; Wang, Y.; Tian, T.; Ikeda, J. Role of leucine-rich pentatricopeptide
repeat motif-containing protein (LRPPRC) for anti-apoptosis and tumourigenesis in cancers. Eur. J. Cancer
2012, 48, 2462–2473.
160. Zou, J.; Yue, F.; Li, W.; Song, K.; Jiang, X.; Yi, J.; Liu, L. Autophagy inhibitor LRPPRC suppresses mitophagy
through interaction with mitophagy initiator Parkin. PLoS ONE 2014, 9, e94903. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
